For patients with metabolic dysfunction–associated steatotic liver disease (MASLD) and diabetes, treatment with a glucagon-like peptide 1 receptor agonist (GLP-1 RA) may protect against progression to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback